Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study
Author
dc.contributor.author
Martorell, A.
Author
dc.contributor.author
Alfageme Roldán, F.
Author
dc.contributor.author
Vilarrasa Rull, E.
Author
dc.contributor.author
Ruiz-Villaverde, R.
Author
dc.contributor.author
Romaní De Gabriel, J.
Author
dc.contributor.author
García Martínez, F.
Author
dc.contributor.author
Vidal Sarro, D.
Author
dc.contributor.author
Velasco Pastor, M.
Author
dc.contributor.author
Ciudad Blanco, C.
Author
dc.contributor.author
Segura Palacios, J. M.
Author
dc.contributor.author
Rodríguez Bandera, A. I.
Author
dc.contributor.author
Pascual Ramírez, J. C.
Author
dc.contributor.author
Sancho Sánchez,
Admission date
dc.date.accessioned
2019-10-30T15:23:51Z
Available date
dc.date.available
2019-10-30T15:23:51Z
Publication date
dc.date.issued
2019
Identifier
dc.identifier.issn
14683083
Identifier
dc.identifier.issn
09269959
Identifier
dc.identifier.other
10.1111/jdv.15710
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/172334
Abstract
dc.description.abstract
Background: It has been reported that clinical evaluation consistently underestimates the severity of hidradenitis suppurativa (HS). Objective: To determine the usefulness of ultrasound as a diagnostic tool in HS compared with clinical examination and to assess the subsequent modification of disease management. Methods: Cross-sectional multicentre study. Severity classification and therapeutic approach according to clinical vs. ultrasound examination were compared. Results: Of 143 HS patients were included. Clinical examination scored 38, 70 and 35 patients as Hurley stage I, II and III, respectively; with ultrasound examination, 21, 80 and 42 patients were staged with Hurley stage I, II and III disease, respectively (P < 0.01). In patients with stage I classification as determined by clinical examination, 44.7% changed to a more severe stage. Clinical examination indicated that 44.1%, 54.5% and 1.4% of patients would maintain, increase or decrease treatment, respectively. For ultrasound examination, these percentages were 31.5%, 67.1% and 1.4% (P < 0.01). Concordance between clinical and ultrasound intra-rater examination was 22.8% (P < 0.01); intra-rater and inter-rater (radiologist) ultrasound agreement was 94.9% and 81.7%, respectively (P < 0.01). Limitations: The inability to detect lesions that measure ≤0.1 mm or with only epidermal location. Conclusion: Ultrasound can modify the clinical staging and therapeutic management in HS by detecting subclinical disease.